REHOVOT, Israel; JERSEY CITY, New Jersey; PHILADELPHIA, December 22 /PRNewswire/ --
- miRview(TM) mets can Accurately Identify the Primary Tumor Site in Patients Presenting With Metastatic Cancer, as Well in Patients Whose Tumor has Been Labeled Cancer of Unknown Primary (CUP)
- In the US Alone Hundreds of Thousands of Patients are Diagnosed Each Year With Metastatic Cancer, and Approximately 70,000 Patients are Diagnosed With CUP Each Year
- Rosetta Genomics Will Hold a Conference Call Today, Monday, December 22nd, at 08:30 am EST, to Discuss the Launch of its microRNA-based Tests